Beijing (1)

Adverse Events (1)

Anlotinib (1)

CA125 (1)

Chemotherapy (1)

Niraparib (1)

Ovarian Carcinoma (1)

Recurrent Ovarian Cancer (1)

Survival Outcomes (1)

Targeted Therapy (1)

Recruiting (1)

phase 2 (1)

Lei Li (1)

niraparib plus anlotinib (1)

combination product (1)

Other (1)

Interventional (1)

niraparib

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Recruiting

Apr 5, 2022